3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Genitourinary
1
CNS
1
Conditions
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Neuroblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Carcinoma, Renal Cell
1
Interventions
fludarabine
6
Tacrolimus
6
Busulfan
6
blinatumomab
5
Rituximab
5
Cyclophosphamide
5
fludarabine phosphate
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
Whole-Body Irradiation
3
Methotrexate
3
Darbepoetin alfa
3
Alemtuzumab
3
ponatinib
2
ibrutinib
2
entrectinib
2
alectinib
2
Thiotepa
2
Therapeutics
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Everolimus
2
Early Intervention, Educational
2
Bone Marrow Transplantation
2
Antilymphocyte Serum
2
vandetanib
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
alectinib
×
Other hematologic neoplasm
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled